|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0032143,
umls-concept:C0035124,
umls-concept:C0038418,
umls-concept:C0038952,
umls-concept:C0042153,
umls-concept:C0155626,
umls-concept:C0205042,
umls-concept:C0256103,
umls-concept:C0439234,
umls-concept:C1274040,
umls-concept:C1947917,
umls-concept:C2348867
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2000-10-26
|
|
pubmed:abstractText |
New recombinant plasminogen activators have been developed to simulate the fibrinolytic action of the physiological serine protease tissue plasminogen activator (alteplase, t-PA), and have prolonged half-life features permitting bolus administration. One such activator, reteplase (r-PA), was compared with t-PA in the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-III Trial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
pubmed-author:ArmstrongP WPW,
pubmed-author:AylwardPP,
pubmed-author:BetriuAA,
pubmed-author:BodeCC,
pubmed-author:CaliffR MRM,
pubmed-author:DalbyAA,
pubmed-author:EmanuelsonHH,
pubmed-author:HochmanJ SJS,
pubmed-author:MoliternoD JDJ,
pubmed-author:OhmanE MEM,
pubmed-author:SapiZZ,
pubmed-author:SimetII,
pubmed-author:SkeneA MAM,
pubmed-author:StebbinsAA,
pubmed-author:TopolE JEJ,
pubmed-author:VahanianAA,
pubmed-author:WhiteH DHD,
pubmed-author:WilcoxRR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
102
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1761-5
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11023929-Acute Disease,
pubmed-meshheading:11023929-Cohort Studies,
pubmed-meshheading:11023929-Female,
pubmed-meshheading:11023929-Fibrinolytic Agents,
pubmed-meshheading:11023929-Follow-Up Studies,
pubmed-meshheading:11023929-Humans,
pubmed-meshheading:11023929-Male,
pubmed-meshheading:11023929-Middle Aged,
pubmed-meshheading:11023929-Myocardial Infarction,
pubmed-meshheading:11023929-Recombinant Proteins,
pubmed-meshheading:11023929-Reperfusion,
pubmed-meshheading:11023929-Streptokinase,
pubmed-meshheading:11023929-Survival Analysis,
pubmed-meshheading:11023929-Tissue Plasminogen Activator,
pubmed-meshheading:11023929-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
|
|
pubmed:affiliation |
Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. topole@ccf.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
